XML 88 R65.htm IDEA: XBRL DOCUMENT v3.25.1
Commitments and Contingencies (Additional Information) (Details) - USD ($)
1 Months Ended 12 Months Ended
Feb. 28, 2013
Dec. 31, 2024
Dec. 31, 2023
Apr. 30, 2023
Commitments and Contingencies [Line Items]        
Royalty expenses   $ 300,000 $ 26,000  
Finance lease liabilities   $ 0    
Finance Lease, Liability, Statement of Financial Position [Extensible Enumeration]   Derivative Liability, Noncurrent    
Lease Expense   $ 1,000,000 1,100,000  
Additional ROU assets   2,225,000 2,943,000 $ 2,500,000
Corresponding lease liabilities   1,523,000 2,237,000 $ 2,500,000
GLOPERBA [Member]        
Commitments and Contingencies [Line Items]        
Due From Related Party   500,000    
Former Employee [Member]        
Commitments and Contingencies [Line Items]        
Agreement settlement payment   3,500,000    
Former Employee One[Member]        
Commitments and Contingencies [Line Items]        
Agreement settlement payment   $ 2,500,000    
Epoladerm [Member]        
Commitments and Contingencies [Line Items]        
Percentage on net sale   6.00%    
Probudur [Member]        
Commitments and Contingencies [Line Items]        
Percentage on net sale   6.00%    
Envelta [Member]        
Commitments and Contingencies [Line Items]        
Percentage on net sale   6.00%    
Product Development Agreement [Member] | Developers [Member]        
Commitments and Contingencies [Line Items]        
Royalty expenses   $ 9,900,000 8,500,000  
Accrued royalty payables   4,000,000 2,400,000  
Agreement maturity date Oct. 02, 2028      
Agreement maturity renewal description The Product Development Agreement will renew automatically for subsequent successive one-year renewal periods unless Scilex Pharma or the Developers terminate it upon six months’ written notice.      
Product Development Agreement [Member] | Developers [Member] | Minimum [Member]        
Commitments and Contingencies [Line Items]        
Royalty payment percentage related to future years 25.00%      
Product Development Agreement [Member] | Developers [Member] | Maximum [Member]        
Commitments and Contingencies [Line Items]        
Royalty payment percentage related to future years 35.00%      
Product Development Agreement [Member] | Scilex Pharma [Member]        
Commitments and Contingencies [Line Items]        
Royalty expenses   $ 8,300,000 $ 8,300,000  
Non-cancelable Lease Agreements [Member] | Minimum [Member] | Research and Development Facilities [Member]        
Commitments and Contingencies [Line Items]        
Operating lease, remaining lease term   2 years 9 months 18 days    
Operating lease, lease term   3 years    
Non-cancelable Lease Agreements [Member] | Maximum [Member] | Research and Development Facilities [Member]        
Commitments and Contingencies [Line Items]        
Operating lease, lease term   5 years